Scott Megaffin

Scott is Chief Executive Officer and President of Adiso Therapeutics, Inc and possesses more than 35 years of successful industry leadership, serving as a senior executive in multiple different settings, including CEO and Board Director at both Fortune 500 pharmaceutical and emerging biotechnology companies. Mr. Megaffin’s has a successful track record leading, fund raising, growing and transacting biopharma organizations. (CEO, Adastra Pharmaceuticals Inc., leading to its acquisition by Cothera Bioscience. President of Churchill Pharmaceuticals leading to its acquisition by Sun Pharma) He possesses far reaching knowledge in a broad number of therapeutic categories including oncology, anti-infectives, inflammation, pain, critical care, and virology. Mr. Megaffin currently serves as a member of the board of Adiso, Adastra and BioNJ.